Search or choose
Find the right test or package.
BCR-ABL Kinase Domain Mutations
Chronic Myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR/ABL fusion protein with constitutive ABL tyrosine kinase activity. The...
DiagnosticsLab test
Know more about this test
Chronic Myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR/ABL fusion protein with constitutive ABL tyrosine kinase acti...
Understanding BCR-ABL Kinase Domain Mutations
Chronic Myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR/ABL fusion protein with constitutive ABL tyrosine kinase activity. The kinase inhibitor imatinib inhibits ABL kinase activity and is now the standard of care for early-phase CML.
Prolonged treatment with Imatinib can lead to drug resistance, especially in patients with advanced disease. This test detects greater than 90 percent...
What does BCR-ABL Kinase Domain Mutations measure?
Chronic Myelogenous leukemia (CML) is characterized by the presence of the Philadelphia chromosome, the product of the t(9;22)(q34;q11) translocation. This translocation results in the BCR/ABL fusion protein with constitutive ABL tyrosine kinase activity. The kinase inhibitor imatinib inhibits ABL kinase activity and is now the standard of care for early-phase CML.
Prolonged treatment with Imatinib can lead to drug resistance, especially in patients with advanced disease. This test detects greater than 90 percent o...
Related parameters
How does home sample collection work?
Select slot
Pick a convenient time.
Phlebotomist visit
A trained expert arrives home.
Safe testing
Samples move through the lab process.
Digital reports
Reports are delivered online.